Lexaria Bioscience Corp. Warrant (LEXXW)

• 1 day: 23.45%
• 5 days: 26.35%
• 1 month: -24.71%
• 3 months: -20.44%
• 6 months: -65.90%
• Year to date: -73.15%
• 1 year: -74.80%
• 5 years: -79.74%
• 10 years: -79.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Employees: 7

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

33% less funds holding

Funds holding: 3 [Q4 2024] → 2 (-1) [Q1 2025]

62% less capital invested

Capital invested by funds: $39.3K [Q4 2024] → $15K (-$24.3K) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1